1. Andersson, B.S., T. Madden, H.T. Tran,W.W. Hu, K.G. Blume, D.S.L. Chow, R.E. Champlin andW.P. Vaughan. Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study. Biology of Blood and Marrow Transplantation 6(5A):548-554, 2000.
  2. Auclair, B., I.W.Wainer and K. Fried. A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model. Pharmaceutical Research 17(10):1228-1235, 2000.
  3. Benincosa, L.J., F.S. Chow, L.P. Tobia, D.C. Kwok, C.B. Davis and W.J. Jusko. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutic 292(2):810-816, 2000.
  4. Britten, C.D., S.D. Baker, L.J. Denis, T. Johnson, R. Drengler, L.L. Siu , K. Duchin, J. Kuhn and E.K. Rowinsky. Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to Paclitaxel. Clinical Cancer Research 6(9):3459- 3468, 2000.
  5. Di Marco, M.P., I.W. Wainer, C.L. Granvil, G. Batist and M.P. Ducharme. New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model. Pharmaceutical Research 17(6):645-652, 2000.
  6. Doan, K.M.M. and K.M.K. Boje. Theoretical pharmacokinetic and pharmacodynamic simulations of drug delivery mediated by blood-brain barrier transporters. Biopharmaceutics and Drug Disposition 21(7):261-278, 2000.
  7. Dowell, J.A., A.R. Sancho, D. Anand and W. Wolf. Noninvasive measurements for studying the tumoral pharmacokinetics of platinum anticancer drugs in solid tumors. Advanced Drug Delivery Reviews 41(1):111-126, 2000.
  8. Drusano, G.L., S.L. Preston, M. Van Guilder, D. North, M. Gombert, M. Oefelein, L. Boccumini, B. Weisinger, M. Corrado and J. Kahn. A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin. Antimicrobial Agents and Chemotherapy 44(8):2046-2051, 2000.
  9. Dutta, S., R. Lal, M.D. Karol, T. Cohen and T. Ebert. Influence of cardiac output on dexmedetomidine pharmacokinetics. Journal of Pharmaceutical Sciences 89(4):519- 527, 2000.
  10. Egan, T.D., A. Sharma, M.A. Ashburn, J. Kievit, N.L. Pace and J.B. Streisand. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 92(3):665-673, 2000.
  11. Fletcher, C.V., S.P. Kawle, T.N. Kakuda, P.L. Anderson, D. Weller, L.R. Bushman, R.C. Brundage and R.P. Remmel. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 14(14):2137- 2144, 2000.
  12. Fracasso, P.M., P.Westerveldt, C.A. Fears, D.M. Rosen, E.G. Zuhowski, L.A. Cazenave, M. Litchman and M.J. Egorin. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. Journal of Clinical Oncology 18(5):1124-1134, 2000.
  13. Groll, A.H., D. Mickiene, K. Werner, R. Petraitiene, V. Petraitis, M. Calendario, A. Field-Ridley, J. Crisp, S.C. Piscitelli and T.J. Walsh. Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrobial Agents and Chemotherapy 44(4):950-957, 2000.
  14. Hanes, S.D., G.C. Wood, V. Herring, M.A. Croce, T.C. Fabian, E. Pritchard and B.A. Boucher. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. American Journal of Surgery 179(6):436-440, 2000.
  15. Holford, N.H.G., H.C. Kimko, J.P.R. Monteleone and C.C. Peck. Simulation of clinical trials. Annual Review of Pharmacology and Toxicology 40:209-234, 2000.
  16. Hough, L.B., A.A. Bagal and S.D. Glick. Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Methods and Findings in Experimental and Clinical Pharmacology 22(2):77-81, 2000.
  17. Houghton, P.J., C.F. Stewart, P.J. Cheshire, L.B. Richmond, M.N. Kirstein, C.A. Poquette, M. Tan, H.S. Friedman and T.P. Brent. Antitumor activity of temozolomide combined with irinotecan is partly independent of O-6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clinical Cancer Research 6(10):4110-4118, 2000.
  18. Hughes, W.T., J.L. Shenep, J.H. Rodman, A. Fridland, R. Willoughby, S. Blanchard, L. Purdue, D.F. Coakley, K.C. Cundy, M. Culnane, B. Zimmer, S. Burchett and J.S. Read. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 44(4):1041-1046, 2000.
  19. Huitema, A.D.R., R.A.A. Mathot, M.M. Tibben, J.H.M. Schellens, S. Rodenhuis and J.H. Beijnen. Validation of techniques for the prediction of Carboplatin exposure: Application of Bayesian methods. Clinical Pharmacology and Therapeutics 67(6):621- 630, 2000.
  20. Jordan, M.K., M.A. Polis, G. Kelly, P.K. Narang, H. Masur and S.C. Piscitelli. Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics. Antimicrobial Agents and Chemotherapy 44(8):2170-2172, 2000.
  21. Krzyzanski, W., A. Chakraborty and W.J. Jusko. Algorithm for application of fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiology International 17(1):77-93, 2000.
  22. Kumar, S., G.R. Tonn, K.W. Riggs and D.W. Rurak. Diphenhydramine disposition in the sheep maternal-placental-fetal unit: Gestational age, plasma drug protein binding, and umbilical blood flow effects on clearance. Drug Metabolism and Disposition 28(3):279-285, 2000.
  23. Kumar, S., H. Wong, S.A. Yeung, K.W. Riggs, F.S. Abbott and D.W. Rurak. Disposition of valproic acid in maternal, fetal, and newborn sheep I: Placental transfer, plasma protein binding, and clearance. Drug Metabolism and Disposition 28(7):845-856, 2000.
  24. Lamarre, P., D. Lebel and M.P. Ducharme. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.Antimicrobial Agents and Chemotherapy 44(2):278-282, 2000.
  25. Laporte-Simitsidis, S., P. Girard, P. Mismetti, S. Chabaud, H. Decousus and J.P. Boissel. Inter-study variability in population pharmacokinetic meta-analysis: When and how to estimate it. Journal of Pharmaceutical Sciences 89(2):155-167, 2000.
  26. Levy, G., M.K. Zamacona and W.J. Jusko. Developing compliance instructions for drug labeling. Clinical Pharmacology and Therapeutics 68(6):586-591, 2000.
  27. Li, X.J., D.G. Feng and K.W. Chen. Optimal image sampling schedule for both imagederived input and output functions in PET cardiac studies. IEEE Transactions on Medical Imaging 19(3):233-242, 2000.
  28. Ma, M.K., W.C. Zamboni, K.M. Radomski, W.L. Furman, V.M. Santana, P.J. Houghton, S.K. Hanna, A.K. Smith and C.F. Stewart. Pharmacokinetics of irinotecan and its metabolites SN-38 and ABC in children with recurrent solid tumors after protracted low-dose irinotecan. Clinical Cancer Research 6(3):813-819, 2000.
  29. McLeod, H.L., J. Cassidy, R.H. Powrie, D.G. Priest, M.A. Zorbas, T.W. Synold, S. Shibata, D. Spicer, D. Bissett, Y.K. Pithavala, M.A. Collier, L.J. Paradiso and J.D. Roberts. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clinical Cancer Research 6(7):2677- 2684, 2000.
  30. Mehvar, R. Development and application of an on-line module for teaching Bayesian forecasting principles in a clinical pharmacokinetics course. American Journal of Pharmaceutical Education 64(2):121-125, 2000.
  31. Migliavacca, F., G. Dubini, G. Pennati, R. Pietrabissa, R. Fumero, T.Y. Hsia and M.R. de Leval. Computational model of the fluid dynamics in systemic-to-pulmonary shunts. Journal of Biomechanics 33(5):549-557, 2000.
  32. Murer, H., N. Hernando, I. Forster and J. Biber. Proximal tubular phosphate reabsorption: Molecular mechanisms. Physiological Reviews 80(4):1373-1409, 2000.
  33. Natalucci, S., M. Boemi and P. Fumelli. One- and two- compartment minimal models detect similar alterations of glucose metabolism indexes in hypertension. Metabolism- Clinical and Experimental 49(12):1529-1536, 2000.
  34. Ouellet, D., A.P. Periclou, R.D. Johnson, J.R. Woodworth and R.L. Lalonde. Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemotherapy and Pharmacology 46(3):227-234, 2000.
  35. Paladino, J.A., D.A. Fong, A. Forrest and R. Ramphal. Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy – For the treatment of febrile episodes in neutropenic patients. Pharmacoeconomics 18(4):369-381, 2000.
  36. Patnaik, A., E. Warner, M. Michael, M.J. Egorin, M.J. Moore, L.L. Siu, P.M. Fracasso, S. Rivkin, I. Kerr, M. Litchman and A.M. Oza. Phase I dose-finding and pharmacokinetic study of paclitaxel and Carboplatin with oral valspodar in patients with advanced solid tumors. Journal of Clinical Oncology 18(21):3677-3689, 2000.
  37. Raschko, J.W., T.W. Synold, W. Chow, P. Coluzzi, V. Hamasaki, L.A. Leong, K.A. Margolin, R.J. Morgan, S.I. Shibata, G. Somlo, M.L. Tetef, Y. Yen, A. ter Veer and J.H. Doroshow. A phase I study of Carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. Cancer Chemotherapy and Pharmacology 46(5):403-410, 2000.
  38. Riva L., S.M. Blaney, R. Dauser, J.G. Nuchtern, J. Durfee, L. McGuffey and S.L. Berg. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clinical Cancer Research 6(3):994-997, 2000.
  39. Rosen, D.A., J.L. Morris, K.R. Rosen, E.R. Nelson, R.J. Steelman, R.A. Gustafson, J.A. Wilhelm, C.T. Chang, J.W. Thackara and R.F. Frye. Nalmefene to prevent epidural narcotic side effects in pediatric patients: A pharmacokinetic and safely study. Pharmacotherapy 20(7):745-749, 2000.
  40. Rousseau, A., P. Marquet, J. Debord, C. Sabot and G. Lachatre. Adaptive control methods for the dose individualisation of anticancer agents. Clinical Pharmacokinetics 38(4):315-353, 2000.
  41. Rowinsky, E.K., T.R. Johnson, C.E. Geyer, L.A. Hammond, S.G. Eckhardt, R. Drengler, L. Smetzer, J. Coyle, J. Rizzo, G. Schwartz, A. Tolcher, D.D. Von Hoff and R.L. De Jager. DX-8951f, a hexacyclic camptothecin analog, on a daily times-five schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. Journal of Clinical Oncology 18(17):3151-3163, 2000.
  42. Ruggeri, A. and M. Martinelli. A program for the optimization of cyclosporine therapy using population kinetics modeling. Computer Methods and Programs in Biomedicine 61(1):61-69, 2000.
  43. Sharkey, E.M., H.B. O’Neill, M.J. Kavarana, H.B. Wang, D.J. Creighton, D.L. Sentz and J.L. Eiseman. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I. Cancer Chemotherapy and Pharmacology 46(2):156-166, 2000.
  44. Sharma A, C.B. Davis, L.A.P. Tobia, D.C. Kwok, M.G. Tucci, E.R. Gore, D.J. Herzyk and T.K. Hart. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. Journal of Pharmacology and Experimental Therapeutics 293(1):33-41, 2000.
  45. Sharma, A., M.J. Goldberg and B.J. Cerimele. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. Journal of Clinical Pharmacology 40(2):161-167, 2000.
  46. Smith, P.F., A. Forrest, C.H. Ballow, D.E. Martin and L. Proulx. Absolute bioavailability and disposition of (-) and (+) 2 ’-deoxy-3 ’-oxa-4’-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrobial Agents and Chemotherapy 44(6):1609-1615, 2000.
  47. Smith, P.F., A. Forrest, C.H. Ballow, D.E. Martin and L. Proulx. Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males. Antimicrobial Agents and Chemotherapy 44(10):2816-2823, 2000.
  48. Snyder S., D.Z. D’Argenio, O. Weislow, J.A. Bilello and G.L. Drusano. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrobial Agents and Chemotherapy 44(4):1051-1058, 2000.
  49. Stafford, M.A., L. Corey, Y.Z. Cao, E.S. Daar, D.D. Ho and A.S. Perelson. Modeling plasma virus concentration during primary HIV infection. Journal of Theoretical Biology 203(3):285-301, 2000.
  50. Stevens, R.C., J.H. Rodman, F.H. Yong, V. Carey, C.A. Knupp and L.M. Frenkel. Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. AIDS Research and Human Retroviruses 16(5):415-421, 2000.
  51. Stowe, C.D., K.R. Lee, S.A. Storgion and S.J. Phelps. Altered phenytoin pharmacokinetics in children with severe, acute traumatic brain injury. Journal of Clinical Pharmacology 40(12):1452-1461, 2000.
  52. Szalai, G., L.E. Williams and F.J. Primus. Tumor targeting with radiolabeled antibodies in a human carcinoembryonic antigen transgenic mouse model. International Journal of Cancer 85(6):751-756, 2000.
  53. Tran, H.T., T. Madden, D. Petropoulos, L.L. Worth, E.A. Felix, H.A. Sprigg-Saenz, M. Choroszy, M. Danielson, D. Przepiorka and K.W. Chan. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplantation 26(5):463-470, 2000.
  54. Tran, J.Q., C.H. Ballow, A. Forrest, J.M. Hyatt, M.F. Sands, C.A. Peloquin and J.J. Schentag. Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables. Journal of Antimicrobial Chemotherapy 45:9-17, 2000.
  55. van den Bongard, H.J.G.D., R.A.A. Mathot, J.H. Beijnen and J.H.M. Schellens. Pharmacokinetically guided administration of chemotherapeutic agents. Clinical Pharmacokinetics 39(5):345-367, 2000.
  56. van den Neste, E., D. de Valeriola, J. Kerger, H. Bleiberg, Z. Kusenda, C. Brassinne, S. Bartholomeus, J. Selleslags, P. Hennebert, H. Wythouck, I. Cazenave, F. Lefresne- Soulas and M. Piccart. A Phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. Clinical Cancer Research 6(1):64-71, 2000.
  57. Venook, A.P., M.J. Egorin, G.L. Rosner, D. Hollis, S. Mani, M. Hawkins, J. Byrd, R. Hohl, D. Budman, N.J. Meropol and M.J. Ratain. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565. Journal of Clinical Oncology 18(14):2780-2787, 2000.
  58. Wall, A.M., A. Gajjar, A. Link, H. Mahmoud, C.H. Pui and M.V. Relling. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 14(2):221-225, 2000.
  59. Williams, L.E., A. Liu, A.M. Wu, P.J. Yazaki, D.M. Yamauchi, G. Lopatin, A.A. Raubitschek and J.Y.C. Wong. Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies. Medical Physics 27(5):988-994, 2000.
  60. Xu, X.C., P. Clarke, G. Szalai, J.E. Shively, L.E. Williams, Y. Shyr, E.G. Shi and F.J. Primus. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Research 60(16):4475-4484, 2000.
  61. Zamboni, W.C., M.J. Egorin, D.A. Van Echo, R.S. Day, B.R. Meisenberg, S.E. Brooks, L.A. Doyle, N.N. Nemieboka, J.M. Dobson, N.S. Tait and K.H. Tkaczuk. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. Journal of Clinical Oncology 18(18):3288-3294, 2000.